Home › Studies › PRJNA995807
PRJNA995807 SRP524575

Synbiotic trial for post-acute COVID-19 syndrome, Hong Kong

A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome: a randomised, double-blind, placebo-controlled trial (RECOVERY trial)

450 gut metagenome samples from Hong Kong, from a randomised, double-blind, placebo-controlled trial testing a synbiotic (SIM01) for post-acute COVID-19 syndrome. machine-written summary

450 samples · 450 runs · HK · Age unknown · 2024 · 6.09 Gbp / sample

Sources
✓Sequence archive 1,800✓Abstract / description 900–Full text–Supplementary tables–External resources–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave
✓ Sequence archive1,800 sample values (collection date, country, latitude, longitude)
✓ Abstract / description900 sample values (health condition, health condition detail)
– Full textno open-access full text linked
– Supplementary tablesno supplementary tables available (or none open access)
– External resourcesnot covered by the external resources we ingest
– User contributionnothing uploaded yet · share metadata
– Human verifiednot yet checked by a person · I checked this project — verify it
Interventions

intervention — arms not resolved

Synbiotic (probiotic + prebiotic) design randomized_controlled_trial · population other_disease · SIM01 synbiotic preparation

“synbiotic preparation (SIM01) for post-acute COVID-19 syndrome” — study.title (study level; per-sample arms are in the intervention column below)

Samples at a glance
1 sampling locations · 1 country
Age
unknown450
Condition
other_disease450
Country
HK450
Body site
primary450
Sequencing depth per sample · this project all projects
all projects, 0–0.03 Gbp: 25,080 samples (4 %)this project, 0–0.03 Gbp: 5 samplesall projects, 0.03–0.1 Gbp: 17,066 samples (3 %)this project, 0.03–0.1 Gbp: 1 samplesall projects, 0.1–0.3 Gbp: 29,179 samples (5 %)all projects, 0.3–1 Gbp: 47,044 samples (8 %)all projects, 1–3 Gbp: 124,983 samples (22 %)this project, 1–3 Gbp: 7 samplesall projects, 3–10 Gbp: 253,728 samples (44 %)this project, 3–10 Gbp: 268 samplesall projects, 10–30 Gbp: 72,533 samples (13 %)this project, 10–30 Gbp: 167 samplesall projects, 30–100 Gbp: 3,024 samples (1 %)this project, 30–100 Gbp: 2 samplesall projects, 100–300 Gbp: 106 samples (0 %)all projects, ≥ 300 Gbp: 9 samples (0 %)project median 6.09 Gbp per sample0130Gbp
Community composition
Phocaeicola 13.7%Bacteroides 11.3%Prevotella 5.6%Faecalibacterium 5.2%Blautia_A 4.1%Roseburia 4.0%Lachnospira 3.7%Bifidobacterium 3.1%Alistipes 2.3%Gemmiger 2.0%Parabacteroides 1.7%Mediterraneibacter 1.6%not assigned to a genus 3.9%other genera 37.8%

Genera, mean relative abundance over 398 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).

Field coverage
fieldsamplescoverageR1R2R3R4
age_category0 0%
country450 100%450
health_condition450 100%450
subject_id0 0%
collection_date450 100%450
health_condition_detail450 100%450
latitude450 100%450
longitude450 100%450
Papers (1)
  • A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. 2024 PMID 38071990 own_data
Details
Archive description

Post-acute COVID-19 syndrome (PACS) affects at least 65 million individuals worldwide but treatment is limited. Whether microbiota modulation is effective in PACS is unknown. We aimed to assess the efficacy of a novel synbiotic preparation (SIM01) on the alleviation of PACS symptoms.

How this project entered the registry

Classified as human gut / stool shotgun DNA metagenome of age unknown by opus_adjudicated with confidence 0.60. Assay shotgun_dna.

  • host study.description · “Post-acute COVID-19 syndrome (PACS) affects at least 65 million individuals”
  • body site sample.attr.isolation_source · “human_stool (n=450/450)”
Evidence examples (one per field × route)
samplefieldvaluerouteconf.sourcequote
SAMN43052190collection_date2023-04R10.90biosample.attribute:collection_date2023-04
SAMN43052190countryHKR10.90sample.attr.geo_loc_nameHong Kong
SAMN43052190health_conditionother_diseaseR40.50paper.abstractpatients with PACS according to the US Centers for Disease Control and Prevention criteria
SAMN43052190health_condition_detailpost-acute COVID-19 syndrome (PACS)R40.50paper.abstractpatients with PACS according to the US Centers for Disease Control and Prevention criteria
SAMN43052190latitude22.3000R10.90biosample.attribute:lat_lon22.30 N 114.17 E
SAMN43052190longitude114.1700R10.90biosample.attribute:lat_lon22.30 N 114.17 E
Sequencing

450 runs over 450 samples · mean 9.90 Gbp per run (median 6.09 Gbp, total 4,456.11 Gbp; 450 runs with a base count) · layout PAIRED 450 · platform ILLUMINA 450 · models Illumina NovaSeq 6000 (450) · 88% of runs with a Sandpiper profile · first public 2024-08-09 – 2024-08-11

Authors (0)

No author record.

Help complete this project

2 of the 4 core fields are below 50% coverage: age_category, subject_id. Share metadata

Downloads

PRJNA995807.csv.gz (11.1 KB) · parquet (85.5 KB) — all 450 samples, every field with route and confidence · PRJNA995807_determinations.csv.gz (15.0 KB) — 2,700 evidence rows

Samples (450 · every field this project has values for · hover a cell for its source)
Loading the sample table…